Carboplatin and ifosfamide and selective consolidation in advanced seminoma

被引:10
作者
Amato, RJ
Ellerhorst, J
Banks, M
Logothetis, CJ
机构
[1] The Department of Genitourinary Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030
关键词
carboplatin; ifosfamide; seminoma;
D O I
10.1016/0959-8049(95)00341-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This prospective phase II study assesses the clinical efficacy and complications of a treatment regimen comprising combination chemotherapy with carboplatin and ifosfamide and selective consolidation in advanced seminoma. Of 43 patients who entered the study, between May 1989 and May 1992, 42 were evaluable. 30 achieved a complete remission (71%; 95% confidence interval, 56-84%) after chemotherapy alone. 10 achieved a complete remission (24%; 95% confidence interval, 13-39%) after chemotherapy plus consolidation. 38 of the 42 patients (91%; 95% confidence interval, 83-98%) remained in remission after a median follow-up period of 35 months (20-56 months). No patient experienced nephrotoxic, neurotoxic, or ototoxic effects, or haemorrhagic cystitis. Ten per cent of the patients had leucopenic fever requiring hospitalisation. Twenty-four per cent required platelet transfusions, and 26% required transfusions of packed red blood cells. For patients with seminoma, treatment with carboplatin and ifosfamide and selective consolidation is safe and effective.
引用
收藏
页码:2223 / 2228
页数:6
相关论文
共 18 条
[1]  
ANSCHER MS, 1992, ONCOLOGY, P97
[2]   RANDOMIZED TRIAL OF ETOPOSIDE AND CISPLATIN VERSUS ETOPOSIDE AND CARBOPLATIN IN PATIENTS WITH GOOD-RISK GERM-CELL TUMORS - A MULTIINSTITUTIONAL STUDY [J].
BAJORIN, DF ;
SAROSDY, MF ;
PFISTER, DG ;
MAZUMDAR, M ;
MOTZER, RJ ;
SCHER, HI ;
GELLER, NL ;
FAIR, WR ;
HERR, H ;
SOGANI, P ;
SHEINFELD, J ;
RUSSO, P ;
VLAMIS, V ;
CAREY, R ;
VOGELZANG, NJ ;
CRAWFORD, ED ;
BOSL, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :598-606
[3]   A RANDOMIZED TRIAL OF ETOPOSIDE + CISPLATIN VERSUS VINBLASTINE + BLEOMYCIN + CISPLATIN + CYCLOPHOSPHAMIDE + DACTINOMYCIN IN PATIENTS WITH GOOD-PROGNOSIS GERM-CELL TUMORS [J].
BOSL, GJ ;
GELLER, NL ;
BAJORIN, D ;
LEITNER, SP ;
YAGODA, A ;
GOLBEY, RB ;
SCHER, H ;
VOGELZANG, NJ ;
AUMAN, J ;
CAREY, R ;
FAIR, WR ;
HERR, H ;
MORSE, M ;
SOGANI, P ;
WHITMORE, W .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (08) :1231-1238
[4]  
CALMAN FMB, 1979, BRIT J UROL, V51, P154
[5]  
CHEBOTAREVA LI, 1964, ACTA UN INT C CANCER, P380
[6]  
FOSSI SD, 1987, J CLIN ONCOL, P1064
[7]  
FREI E, 1988, CANCER RES, V48, P6417
[8]   DIAMMINODICHLOROPLATINUM IN CHEMOTHERAPY OF TESTICULAR TUMORS [J].
HIGBY, DJ ;
WALLACE, HJ ;
ALBERT, D ;
HOLLAND, JF .
JOURNAL OF UROLOGY, 1974, 112 (01) :100-104
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]   THE IMPORTANCE OF BLEOMYCIN IN COMBINATION CHEMOTHERAPY FOR GOOD-PROGNOSIS GERM-CELL CARCINOMA [J].
LEVI, JA ;
RAGHAVAN, D ;
HARVEY, V ;
THOMPSON, D ;
SANDEMAN, T ;
GILL, G ;
STUARTHARRIS, R ;
SNYDER, R ;
BYRNE, M ;
KERESTES, Z ;
MARGRIE, S .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1300-1305